Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allocetra-OTS in Severe or Critical COVID-19 with ARDS (Phase 2b)
2021-003246-20Phase 2Completed
- Sponsor
- Enlivex Therapeutics
- Start
- Jul 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Allocetra in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (4 arms), sponsored by Enlivex Therapeutics. Primary endpoints: Primary composite endpoint (severely ill cohort) and Primary composite endpoint (critically ill cohort). Started Jul 2021; status: completed.
02
Drugs
Allocetra
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2021-003246-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003246-20.